SCHEMBL22972196

SCHEMBL22972196

Cc1c(Oc2ccnc3cc(C(F)(F)F)ccc23)cccc1C(=O)NCc1ccncc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SORT1 Q99523 2/20 0.51
POLB P06746 1/20 0.47
KDR P35968 6/20 0.46
ELANE P08246 1/20 0.45
MAPK1 P28482 1/20 0.44
GPR52 Q9Y2T5 3/20 0.44
AURKA O14965 2/20 0.44
MET P08581 2/20 0.44
TEK Q02763 2/20 0.44
LCK P06239 1/20 0.44
AURKB Q96GD4 1/20 0.44
MAPK14 Q16539 2/20 0.43
HTR2B P41595 1/20 0.42
BRAF P15056 1/20 0.42
TNNI3K Q59H18 1/20 0.42
ABL1 P00519 1/20 0.42
EGFR P00533 1/20 0.42
CSF1R P07333 1/20 0.42
PDGFRB P09619 1/20 0.42
KIT P10721 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22971978 0.90 POLB (0.49) POLBKDRMAPK1AURKAMET
SCHEMBL22972197 0.88 KDR (0.46) POLBKDRMAPK1GPR52AURKA
SCHEMBL22971870 0.87 POLB (0.48) POLBKDRMAPK1AURKAMET
SCHEMBL22971899 0.87 POLB (0.48) POLBKDRMAPK1AURKAMET
SCHEMBL22972029 0.87 POLB (0.48) POLBKDRMAPK1AURKAMET
SCHEMBL22971946 0.87 MAPT (0.48) POLBKDRMAPK1AURKAMET
SCHEMBL22972316 0.87 POLB (0.57) POLBMAPK1MAPK14
SCHEMBL22972321 0.86 KDR (0.56) POLBKDRAURKAMETTEK
SCHEMBL22972348 0.86 POLB (0.47) POLBKDRMAPK1AURKAMET
SCHEMBL22972422 0.86 POLB (0.47) POLBKDRMAPK1AURKAMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220388979-A1 QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS B.C.I. PHARMA (BE) 2022-12-08 US disclosed
WO-2021023888-A1 ISOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS B.C.I. PHARMA (BE) 2021-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220388979-A1 QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS ABL1, PHKB, EEF2K SORT1 4783/4885POLB 2127/4885KDR 604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.